Literature DB >> 6287350

Orthostatic hypotension in familial amyloid polyneuropathy: treatment with DL-threo-3,4-dihydroxyphenylserine.

T Suzuki, S Higa, S Sakoda, A Hayashi, Y Yamamura, Y Takaba, A Nakajima.   

Abstract

We measured plasma norepinephrine levels in patients with familial amyloid polyneuropathy. Patients with orthostatic hypotension had low basal plasma norepinephrine levels, which did not increase after postural change. On the basis of biochemical findings that suggest depletion of peripheral norepinephrine, DL-threo-3,4-dihydroxyphenylserine, an immediate precursor of norepinephrine, was given orally. Six hundred mg of this drug induced substantial and sustained elevation of blood pressure for several hours, and plasma norepinephrine content increased. Daily administration for 4 weeks improved postural dizziness and syncope, and daily activity increased.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6287350     DOI: 10.1212/wnl.31.10.1323

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  17 in total

1.  Deficient vesicular storage: A common theme in catecholaminergic neurodegeneration.

Authors:  David S Goldstein; Courtney Holmes; Patti Sullivan; Deborah C Mash; Ellen Sidransky; Alessandro Stefani; Irwin J Kopin; Yehonatan Sharabi
Journal:  Parkinsonism Relat Disord       Date:  2015-07-17       Impact factor: 4.891

2.  The aortic alpha 1-adrenergic receptor in familial amyloidotic polyneuropathy.

Authors:  T Azuma; Y Watanabe; T Suzuki; S Sakoda; S Higa; R Mizuno; S Tsujino; S Kishimoto; H Yoshida
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

3.  Acute autonomic and sensory neuropathy: a case report.

Authors:  F Kanda; T Uchida; K Jinnai; K Tada; S Shiozawa; T Fujita; A Ohnishi
Journal:  J Neurol       Date:  1990-02       Impact factor: 4.849

4.  Droxidopa for symptomatic neurogenic orthostatic hypotension: what can we learn?

Authors:  Horacio Kaufmann
Journal:  Clin Auton Res       Date:  2017-06-16       Impact factor: 4.435

Review 5.  Amine precursor amino acid therapy: from neurochemical basis to clinical aspects.

Authors:  T Nakajima
Journal:  Neurochem Res       Date:  1996-02       Impact factor: 3.996

6.  Reversal of the reserpine-induced ptosis by L-threo-3,4-dihydroxy-phenylserine (L-threo-DOPS), a (-)-norepinephrine precursor, and its potentiation by imipramine or nialamide.

Authors:  T Kato; M Katsuyama; N Karai; A Hirose; M Nakamura; J Katsube
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-03       Impact factor: 3.000

7.  Disturbed function of the pineal gland in familial amyloid polyneuropathy.

Authors:  S Higa; T Suzuki; S Sakoda; S Kishimoto; Y Takaba; A Nakajima; S P Markey
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

8.  Acute pandysautonomia: mass spectrometric and histopathological studies of the sympathetic nervous system during long term L-threo-3,4-dihydroxyphenylserine treatment.

Authors:  M Ushiyama; S Ikeda; T Suzuki; M Yazawa; N Yanagisawa; S Tsujino
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-07       Impact factor: 10.154

9.  Droxidopa in neurogenic orthostatic hypotension.

Authors:  Horacio Kaufmann; Lucy Norcliffe-Kaufmann; Jose-Alberto Palma
Journal:  Expert Rev Cardiovasc Ther       Date:  2015-06-19

10.  Pharmacokinetic studies of oral L-threo-3,4-dihydroxyphenylserine in normal subjects and patients with familial amyloid polyneuropathy.

Authors:  T Suzuki; S Higa; S Sakoda; M Ueji; A Hayashi; Y Takaba; A Nakajima
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.